Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy (Q40138970)

17 September 2017

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy (English)

1 reference

17 September 2017

1 reference

1 reference

1 reference

9

Rachel Schiff

1 reference

17 September 2017

Grazia Arpino

1

1 reference

17 September 2017

Carolina Gutierrez

2

1 reference

17 September 2017

Heidi Weiss

3

1 reference

17 September 2017

Mothaffar Rimawi

4

1 reference

17 September 2017

Suleiman Massarweh

5

1 reference

17 September 2017

Lavina Bharwani

6

1 reference

17 September 2017

Sabino De Placido

7

1 reference

17 September 2017

C Kent Osborne

8

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Journal of the National Cancer Institute

17 September 2017

1 reference

17 September 2017

99

1 reference

17 September 2017

9

1 reference

17 September 2017

694-705

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

17 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Aromatase inhibitors: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

ErbB-targeted therapeutic approaches in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

RETRACTED: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fr

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJK151

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJK151

1 reference

17 September 2017

1 reference